Emgality® ▼ (galcanezumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Emgality Summary of Product Characteristics (SmPC)

Emgality® (galcanezumab) Pen: Information on Needle

The pre-filled pen comes with a 27 gauge (thin wall) x 12.7 mm permanently built in needle.

General information

The needle is built into the cartridge that is inside the pen and cannot be changed or taken off. The needle or needle attachment must not be touched.1

The needle included in the pack is only suitable for subcutaneous injection.2

Dripping from the Needle

A drop of medicine may be seen when the base cap is removed. It is okay to see a drop of liquid on the tip of the needle.3 This will not affect the dose. 1

Pre-Filled Pen Function: Needle Retraction

When the medicine is completely delivered, the needle begins to travel upward (retract). The patient may feel the needle travel upwards in the pen. The second loud click is heard right before the needle stops retracting. The whole process of the needle retraction occurs very quickly.1

If the needle does not retract after the injection the needle  must not be touched and the base cap must not be replaced. The pen must be stored in a safe place to avoid an accidental needlestick injury. Patients can contact their doctor, pharmacist or nurse for instructions on how to return the pen.3

The instructions for using the pen included with the Package Leaflet, must be followed carefully. The pre-filled pen is for total use only.2

After training, patients may self-inject galcanezumab if a healthcare professional determines that it is appropriate. 2

References

1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2. Emgality [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

3. Emgality [instructions for use]. Eli Lilly Nederland B.V., The Netherlands.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: February 15, 2019

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question